Press Release ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial 7 May 2025
Press Release Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment 7 May 2025
Press Release California Elected Officials Asked to Take Immediate Action Vowing to Reverse Affordability Crisis 7 May 2025
Press Release Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 7 May 2025
Press Release Ant International Partners with Barclays on Global Treasury Management with Proprietary AI-Powered FX Model 7 May 2025
